Methocinnamox (MCAM): A novel õ-opioid receptor antagonist for opioid use disorders

Methocinnamox (MCAM)：一种新型 α-阿片受体拮抗剂，用于治疗阿片类药物使用障碍

• 批准号: 10763458
• 负责人: CHARLES P FRANCE
• 金额: $ 421.81万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-30 至 2026-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10763458
• 关键词: Methocinnamox; MCAM; novel; opioid; receptor

MCAM is a novel opioid antagonist whose advantages over naloxone for opioid overdose include a pseudo-irreversible interaction with the µ opioid receptor, and a much longer duration of action. These attributes indicate better reversal of the respiratory depressant effects of very potent and/or very long lasting opioid receptor agonists and better treatment of opioid use disorder. Proof-of-concept studies in non human primates demonstrate MCAM’s long duration of action against the reinforcing and respiratory-depressant effects of remifentanil and heroin, respectively. Doses of MCAM that were 10 times larger than those that protected against the effects of mu opioid receptor agonists had no effect on food-maintained responding in rhesus monkeys, and did not modify blood pressure, heart rate or body temperature. This proposal seeks funding for composition and study of the pharmacodynamics of MCAM (UG3 portion). In the UH3 portion, GMP-MCAM will be studied in additional pharmacodynamics assays and animal toxicity and safety studies. An IND application, following consultation with the FDA will be sought using these data. Contract Research Organizations have been identified for each stage of the proposal. The proposal describes the necessary and sufficient conditions from which to establish MCAM’s safety and antagonist activity in animals and humans. MCAM may be able to prevent all actions of any μ-receptor opioid drug in humans for a longer period of time than any other antagonist given acutely. MCAM offers potential therapeutic objectives that are not achieved with any other drug. The successful execution of this proposal will establish these claims.

MCAM是一种新型阿片类药物拮抗剂，与纳洛酮相比，其在阿片类药物过量方面的优势包括 与μ阿片受体的假不可逆相互作用，以及更长的作用持续时间。这些 这些属性表明，非常有效和/或非常长时间的呼吸抑制效应的逆转更好， 持久的阿片受体激动剂和更好的治疗阿片类药物使用障碍。概念验证研究， 非人类灵长类动物证明了MCAM对强化和 瑞芬太尼和海洛因的麻醉效果。MCAM的剂量为10 比那些保护免受μ阿片受体激动剂作用的细胞大10倍的细胞没有作用， 对恒河猴的食物维持反应，并没有改变血压，心率或 体温 该提案旨在为MCAM（UG 3）的组成和药效学研究提供资金 部分）。在UH 3部分，将在其他药效学试验中研究GMP-MCAM， 动物毒性和安全性研究。在与FDA协商后，将寻求IND申请 使用这些数据。 合同研究组织已确定为每个阶段的建议。该提案 描述了确定MCAM安全性和拮抗剂的必要和充分条件 在动物和人类中的活动。MCAM可能能够阻止任何μ受体阿片类药物的所有作用 在人类中的作用时间比任何其他拮抗剂都要长。MCAM提供潜力 这是任何其他药物都无法达到的治疗目的。成功执行这一 提案将确立这些主张。